The 6-month followup may be too short to adequately show clinically relevant changes in the patients' actual activity level.
Retinal and neuronal function may take longer than 1 year after bariatric surgery to show clinically meaningful changes.
Normal populations may show little change on clinically validated outcome measures, control groups may experience contamination 40 and, because the effects of parenting on health and social outcomes appear to be life long, cost-effectiveness, essential to inform decision making, may be difficult to establish.
It may be clinically silent, patients may show only vague symptoms or present with extraintestinal problems including psychiatric, neurologic, bone, liver or reproductive disorders or as malignancy [ 9- 12].
The majority of SLC16A2 mutations results in complete loss of function, although few mutations with clinically milder phenotypes may show residual transporter activity.
This finding suggests that patients with clinically active disease may show no FDG-avid lesions before treatment onset, but nevertheless should be candidates for imatinib mesylate therapy.
It is estimated that between 10 and 30%% of dogs with a clinically confirmed canine AD may show a negative IDT [ 49, 50].
As Cittadini and colleagues showed, HC might be more clinically variable than known so far, and its phenotype may show features of migraine or the Trigeminal Autonomic Cephalalgias (TACs) [2].
As this was not the primary, or even a prospectively defined, analysis of data from study MS-F203, inadequate sample sizes may have precluded us from showing clinically important differences at all time points.
